Current Awareness: 9th International Symposium on Bioluminescence and Chemiluminescence,Marine Biological Laboratory,Woods Hole,MA, USA 4–8 October 1996 (remaining abstracts)

The following abstracts were not received in time to be included in the published collection of abstracts (J Biolumin Chemilumin 1996: 11:231-65). The three papers that follow were unable to be presented at the symposium and have not been peer reviewed. The symposium proceedings were published in the volume Bioluminescence and Chemiluminescence: Molecular Reporting with Photons, edited by J W Hastings, L J Kricka and PE Stanley, Chichester: Wiley,1997. © 1997 John Wiley & Sons, Ltd.     

International Symposium on Emerging Clinical and Pharmaceutical Applications of Bioluminescence and Chemiluminescence,Fort Lauderdale,Florida, USA, 14–16 February 1993

The abstracts of the talks and posters at this recent two day meeting are reproduced below. An exhibit of equipment and reagents was also held concurrently with the meeting.     

Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

The platinum-based drugs, cisplatin and carboplatin, represent major agents in the chemotherapeutic treatment of a variety of types of cancer. Novel, "third-generation" agents aimed at broadening the clinical activity of this class of drug are currently undergoing clinical evaluation. These include oxaliplatin, ZD0473 and BBR3464. Clinical trials and preclinical studies are also being conducted with liposomal (SPI-077 and L-NDDP) and polymeric platinum complexes (linked to HPMA or albumin). Combination studies of cisplatin/carboplatin with other anticancer drugs such as gemcitabine and UCN-01 (7-hydroxystaurosporine) and agents designed to reduce platinum drug toxicities (e.g., BNP-7787, DIMESNA) are ongoing. Preclinically, there is interest in trans platinum complexes, terpyridine platinum(II) complexes and other metal-containing agents (ruthenium and gold).